New poll reveals Americans' mixed views on weight-loss drugs for obesity treatment, especially regarding teen use.

More than half of adults with overweight or obesity prescribed a GLP-1 discontinue their drug within 1 year, with discontinuation rates higher for those without type 2 diabetes, researchers reported ...

New poll shows about half of U.S. adults believe it is a good thing for adults to use weight-loss drugs if they are ...

Echoing Iselin's assessment, Fallon Health CEO Manny Lopes said both providers and payers are at a "crisis point." Meanwhile, ...

Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as ...

Weight loss medications and injections have become very popular in the past two years, but they must be used in conjunction ...

One recent analysis found that, over the course of three years, people taking semaglutide (the compound in Ozempic and the weight loss drug Wegovy) were about 40 to 70 percent less likely to be ...

CBS News Miami investigates the financial hurdles surrounding these medications and explores alternatives that may offer a ...

Weight-loss drug developer Metsera has raised $275 million after pricing its U.S. initial public offering at $18 per share, above its targeted range, the ARCH Venture Partners-backed biotech company ...

Weight-loss drugs are transforming health care and Wall Street, but exciting prospects don’t necessarily mean a company is a good investment.